Theralase Technologies (CVE:TLT) Trading 7.8% Higher - Here's Why

Key Points

• Shares jumped 7.8% to C$0.28 on Friday (high C$0.28, prior close C$0.26), with 298,584 shares traded—up 66% versus the average session volume.
• Theralase is a clinical-stage pharmaceutical developer of light-activated photodynamic compounds and proprietary super-pulsed laser technology; the company has a market cap of C$75.36M and a negative P/E (-15.56), indicating it remains unprofitable.

Theralase Technologies Inc. (CVE:TLT - )'s stock price traded up 7.8% during trading on Friday . The stock traded as high as C$0.28 and last traded at C$0.28. 298,584 shares traded hands during trading, an increase of 66% from the average session volume of 180,133 shares. The stock had previously closed at C$0.26.

Theralase Technologies Stock Performance

The stock has a market cap of C$75.36 million, a P/E ratio of -15.56 and a beta of -0.31. The company has a fifty day moving average of C$0.28 and a 200 day moving average of C$0.22. The company has a debt-to-equity ratio of 29.26, a current ratio of 0.83 and a quick ratio of 3.40.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.